Targeted therapy of acute myeloid leukemia

References

• American Cancer Society. Cancer Facts & Figures 2014. American Cancer Society; Atlanta: 2014
   Google Scholar
• Thein MS, Ershler WB, Jemal A, et al. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer 2013;119(15):2720-7
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368(22):2059-74
   PubMed Web of Science ®Google Scholar
• Zheng PZ, Wang KK, Zhang QY, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA 2005;102(21):7653-8
   PubMedGoogle Scholar
• Mueller BU, Pabst T, Fos J, et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 2006;107(8):3330-8
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349(21):2042-54
   PubMed Web of Science ®Google Scholar
• Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 2012;119(24):5824-31
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363(25):2424-33
   PubMed Web of Science ®Google Scholar
• Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012;30(7):742-50
   PubMed Web of Science ®Google Scholar
• Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia 2012;26(6):1247-54
   PubMed Web of Science ®Google Scholar
• Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res 2013;37(11):1445-50
   PubMed Web of Science ®Google Scholar
• Russler-Germain DA, Spencer DH, Young MA, et al. The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active Tetramers. Cancer Cell 2014;25(4):442-54
   PubMed Web of Science ®Google Scholar
• Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011;43(4):309-15
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012;26(5):1106-7
   PubMed Web of Science ®Google Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 2014;28(1):78-87
   PubMed Web of Science ®Google Scholar
• Neff T, Armstrong SA. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood 2013;121(24):4847-53
   PubMedGoogle Scholar
• Feng Q, Wang H, Ng HH, et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 2002;12(12):1052-8
   PubMed Web of Science ®Google Scholar
• Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005;121(2):167-78
   PubMed Web of Science ®Google Scholar
• Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011;20(1):66-78
   PubMed Web of Science ®Google Scholar
• Nguyen AT, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 2011;117(25):6912-22
   PubMed Web of Science ®Google Scholar
• Deshpande AJ, Chen L, Fazio M, et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 2013;121(13):2533-41
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013;122(6):1017-25
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011;20(1):53-65
   PubMed Web of Science ®Google Scholar
• Klaus CR, Daigle SR, Iwanowics D, et al. DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL-Rearranged Leukemia Cells [abstract]. Blood 2013;122(21):3930
   Google Scholar
• A First-in-human phase 1 and expanded cohort study of epz-5676 in advanced hematologic malignancies, including acute leukemia with rearrangement of the MLL Gene. Available from: https://clinicaltrials.gov/ct2/show/NCT01684150
   Google Scholar
• Schwartz YB, Pirrotta V. A new world of Polycombs: unexpected partnerships and emerging functions. Nat Rev Genet 2013;14(12):853-64
   PubMed Web of Science ®Google Scholar
• Xiao B, Wilson JR, Gamblin SJ. SET domains and histone methylation. Curr Opin Struct Biol 2003;13(6):699-705
   PubMed Web of Science ®Google Scholar
• Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001;112(4):950-8
   PubMed Web of Science ®Google Scholar
• Chen J, Li J, Han Q, et al. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. Exp Biol Med 2012;237(9):1110-16
   Google Scholar
• Shen X, Liu Y, Hsu YJ, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008;32(4):491-502
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419(6907):624-9
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42(2):181-5
   PubMed Web of Science ®Google Scholar
• Ryan RJ, Nitta M, Borger D, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 2011;6(12):e28585
   PubMed Web of Science ®Google Scholar
• Zhao X, Lwin T, Zhang X, et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 2013;27(12):2341-50
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012;22(4):506-23
   PubMed Web of Science ®Google Scholar
• Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas. Available from: https://clinicaltrials.gov/ct2/show/NCT01897571
   Google Scholar
• A Study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2816126 in subjects with relapsed/refractory diffuse large b cell and transformed follicular lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02082977
   Google Scholar
• Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010;42(8):665-7
   PubMed Web of Science ®Google Scholar
• Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Gene Dev 2012;26(7):651-6
   PubMed Web of Science ®Google Scholar
• Tanaka S, Miyagi S, Sashida G, et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012;120(5):1107-17
   PubMed Web of Science ®Google Scholar
• Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009;114(13):2733-43
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012;149(1):214-31
   PubMed Web of Science ®Google Scholar
• French CA, Miyoshi I, Kubonishi I, et al.4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003;63(2):304-7
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478(7370):524-8
   PubMed Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478(7370):529-33
   PubMed Web of Science ®Google Scholar
• Dawson MA, Gudgin EJ, Horton SJ, et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 2014;28(2):311-20
   PubMed Web of Science ®Google Scholar
• Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009;23(10):1731-43
   PubMed Web of Science ®Google Scholar
• Herait PE, Berthon C, Thieblemont C, et al. BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; Apr 5-9, San Diego Philadelphia (PA): AACR 2014; Abstract nr CT231
   Google Scholar
• A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015 in Haematological Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT01713582
   Google Scholar
• A two part, multicenter, open-label study of TEN-010 Given subcutaneously. Available from: https://clinicaltrials.gov/ct2/show/NCT01987362
   Google Scholar
• A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01949883
   Google Scholar
• Dinner SN, Giles FJ, Altman JK. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research. Curr Opin Hematol 2014;21(2):79-86
   PubMed Web of Science ®Google Scholar
• McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest 2013;123(9):3672-7
   PubMed Web of Science ®Google Scholar
• Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314(5797):268-74
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321(5897):1807-12
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28(14):2348-55
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361(11):1058-66
   PubMed Web of Science ®Google Scholar
• Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013;339(6127):1621-5
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19(1):17-30
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011;12(5):463-9
   PubMed Web of Science ®Google Scholar
• Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340(6132):622-6
   PubMed Web of Science ®Google Scholar
• Yen K, Lemieux R, Popovici-Muller J, et al. IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit with ara-c in a primary human Idh1 Mutant AML Xenograft Model. Blood 2013;122(21):3946
   Google Scholar
• Yen K, Wang F, Travins J, et al. AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model. Blood 2013;122(21):240
   Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18(6):553-67
   PubMed Web of Science ®Google Scholar
• Stein E, Tallman M, Pollyea DA, et al. Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5-9 April 2014, San Diego Philadelphia (PA): AACR 2014; Abstract nr CT103
   Google Scholar
• Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation. Available from: https://clinicaltrials.gov/ct2/show/NCT02074839
   Google Scholar
• Phase 1 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation. Available from: https://clinicaltrials.gov/ct2/show/NCT01915498
   Google Scholar
• Hitzerd SM, Verbrugge SE, Ossenkoppele G, et al. Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids 2014;46(4):793-808
   PubMed Web of Science ®Google Scholar
• Krige D, Needham LA, Bawden LJ, et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res 2008;68(16):6669-79
   PubMed Web of Science ®Google Scholar
• Cifaldi L, Romania P, Lorenzi S, et al. Role of endoplasmic reticulum aminopeptidases in health and disease: from infection to cancer. Int J Mol Sci 2012;13(7):8338-52
   PubMedGoogle Scholar
• Fruci D, Ferracuti S, Limongi MZ, et al. Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines. J Immunol 2006;176(8):4869-79
   PubMed Web of Science ®Google Scholar
• Piedfer M, Dauzonne D, Tang R, et al. Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J 2011;25(8):2831-42
   PubMedGoogle Scholar
• Lowenberg B, Morgan G, Ossenkoppele GJ, et al. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol 2010;28(28):4333-8
   PubMed Web of Science ®Google Scholar
• Cortes J, Feldman E, Yee K, et al. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol 2013;14(4):354-62
   PubMed Web of Science ®Google Scholar
• Mawad R, Becker PS, Hendrie PC, et al. A Phase II study of tosedostat (TST) in combination with either cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukemia (AML) Or high-risk myelodysplastic syndrome (MDS). Blood 2013;122:21
   Google Scholar
• DiNardo CD, Kantarjian HM, Ravandi F, et al. A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS. Blood 2013;122(21):2698
   Google Scholar
• Moore HE, Davenport EL, Smith EM, et al. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther 2009;8(4):762-70
   PubMed Web of Science ®Google Scholar
• Reid AH, Protheroe A, Attard G, et al. A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin Cancer Res 2009;15(15):4978-85
   PubMed Web of Science ®Google Scholar
• van Herpen CM, Eskens FA, de Jonge M, et al. A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours. Br J Cancer 2010;103(9):1362-8
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Giles FJ, Swords RT. The PIM kinases in hematological cancers. Expert Rev Hematol 2012;5(1):81-96
   PubMed Web of Science ®Google Scholar
• Cuypers HT, Selten G, Quint W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984;37(1):141-50
   PubMed Web of Science ®Google Scholar
• Meeker TC, Nagarajan L, ar-Rushdi A, et al. Characterization of the human PIM-1 gene: a putative proto-oncogene coding for a tissue specific member of the protein kinase family. Oncogene Res 1987;1(1):87-101
   PubMedGoogle Scholar
• Qian KC, Wang L, Hickey ER, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 2005;280(7):6130-7
   PubMed Web of Science ®Google Scholar
• Wang Z, Bhattacharya N, Mixter PF, et al. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002;1593(1):45-55
   PubMed Web of Science ®Google Scholar
• Swords R, Kelly K, Carew J, et al. The Pim kinases: new targets for drug development. Curr Drug Targets 2011;12(14):2059-66
   PubMed Web of Science ®Google Scholar
• Lilly M, Sandholm J, Cooper JJ, et al. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999;18(27):4022-31
   PubMed Web of Science ®Google Scholar
• Fox CJ, Hammerman PS, Cinalli RM, et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Gene Dev 2003;17(15):1841-54
   PubMedGoogle Scholar
• Wang J, Kim J, Roh M, et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 2010;29(17):2477-87
   PubMedGoogle Scholar
• Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 2008;27(35):4809-19
   PubMed Web of Science ®Google Scholar
• Zippo A, Serafini R, Rocchigiani M, et al. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 2009;138(6):1122-36
   PubMedGoogle Scholar
• Grundler R, Brault L, Gasser C, et al. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 2009;206(9):1957-70
   PubMed Web of Science ®Google Scholar
• Amson R, Sigaux F, Przedborski S, et al. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989;86(22):8857-61
   PubMed Web of Science ®Google Scholar
• Cohen AM, Grinblat B, Bessler H, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2004;45(5):951-5
   PubMed Web of Science ®Google Scholar
• Tamburini J, Green AS, Bardet V, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009;114(8):1618-27
   PubMed Web of Science ®Google Scholar
• Hsi ED, Jung SH, Lai R, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008;49(11):2081-90
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100(17):9991-6
   PubMed Web of Science ®Google Scholar
• Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 2014;123(6):905-13
   PubMed Web of Science ®Google Scholar
• Safety, Tolerability, pharmacokinetics and efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01489722
   Google Scholar
• Garcia PD, Langowski JL, Wang Y, et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res 2014;20(7):1834-45
   PubMed Web of Science ®Google Scholar
• Lu J, Zavorotinskaya T, Dai Y, et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood 2013;122(9):1610-20
   PubMed Web of Science ®Google Scholar
• Fathi AT, Arowojolu O, Swinnen I, et al. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res 2012;36(2):224-31
   PubMed Web of Science ®Google Scholar
• Raab MS, Ocio EM, Thomas SK, et al. Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/Refractory Multiple Myeloma [abstract]. Blood 2013;122(21):3186
   Google Scholar
• Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias. Available from: https://clinicaltrials.gov/ct2/show/NCT01239108
   Google Scholar
• A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS). Available from: https://clinicaltrials.gov/ct2/show/NCT02078609
   Google Scholar
• Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-18
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100(13):4372-80
   PubMed Web of Science ®Google Scholar
• Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008;111(3):1552-9
   PubMed Web of Science ®Google Scholar
• Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26(10):2176-85
   PubMed Web of Science ®Google Scholar
• Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012;26(9):2061-8
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28(28):4339-45
   PubMed Web of Science ®Google Scholar
• Randhawa JK, Kantarjian HM, Borthakur G, et al. Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. Blood 2014;124(21):389
   Google Scholar
• A Safety and tolerability study of crenolanib in combination with chemotherapy in newly diagnosed acute myeloid leukemia patients with FLT3 Mutations. Available from: https://clinicaltrials.gov/ct2/show/NCT02283177
   Google Scholar
• Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013;31(29):3681-7
   PubMed Web of Science ®Google Scholar
• Borthakur G, Kantarjian HM, O’Brien S, et al. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood 2014;124(21):388
   Google Scholar
• An open-label study of quizartinib monotherapy vs. salvage chemotherapy in Acute Myeloid Leukemia (AML) Subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT02039726
   Google Scholar
• Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther 2013;138(2):255-71
   PubMed Web of Science ®Google Scholar
• Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010;10(12):825-41
   PubMed Web of Science ®Google Scholar
• Wang ZX, Xue D, Liu ZL, et al. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. Int J Biochem Cell Biol 2012;44(1):200-10
   PubMedGoogle Scholar
• Weichert W, Kristiansen G, Schmidt M, et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005;11(36):5644-50
   PubMed Web of Science ®Google Scholar
• Renner AG, Dos Santos C, Recher C, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009;114(3):659-62
   PubMed Web of Science ®Google Scholar
• Rudolph D, Steegmaier M, Hoffmann M, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15(9):3094-102
   PubMed Web of Science ®Google Scholar
• Steegmaier M, Hoffmann M, Baum A, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17(4):316-22
   PubMed Web of Science ®Google Scholar
• Gjertsen BT, Schoffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 2015;29(1):11-19
   PubMed Web of Science ®Google Scholar
• Rudolph D, Albrecht C, Geiselmann L, et al. Efficacy of the Plk Inhibitor Volasertib in Preclinical Models of AML. Blood 2014;124(21):2307
   Google Scholar
• Olmos D, Barker D, Sharma R, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2011;17(10):3420-30
   PubMed Web of Science ®Google Scholar
• Casolaro A, Golay J, Albanese C, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One 2013;8(3):e58424
   Google Scholar
• Bug G, Schlenk RF, Muller-Tidow C, et al. Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine. ASH Annual Meeting Abstracts 2010;116(21):3316
   Google Scholar
• Dohner H, Lubbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 2014;124(9):1426-33
   PubMed Web of Science ®Google Scholar
• Volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for Intensive Remission Induction Therapy (POLO-AML-2). Available from: https://clinicaltrials.gov/ct2/show/NCT01721876
   Google Scholar
• Volasertib + decitabine in patients with acute myeloid leukemia (AML). Available from: https://clinicaltrials.gov/ct2/show/NCT02003573
   Google Scholar
• Haynes BF, Hemler ME, Mann DL, et al. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 1981;126(4):1409-14
   PubMed Web of Science ®Google Scholar
• Cantor J, Slepak M, Ege N, et al. Loss of T cell CD98 H chain specifically ablates T cell clonal expansion and protects from autoimmunity. J Immunol 2011;187(2):851-60
   PubMed Web of Science ®Google Scholar
• Cantor J, Browne CD, Ruppert R, et al. CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat Immunol 2009;10(4):412-19
   PubMed Web of Science ®Google Scholar
• Mori K, Miyamoto N, Higuchi Y, et al. Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. Cell Immunol 2001;207(2):118-26
   PubMedGoogle Scholar
• Holte H, Davies CD, Kvaloy S, et al. The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas. Int J Cancer 1987;39(5):590-4
   PubMedGoogle Scholar
• Taskov H, Pashov A, ffmitrova E, et al. Levels of CAF7 (CD98) expression correlate with the complete remission duration in childhood acute leukemia. Leuk Res 1996;20(1):75-9
   PubMedGoogle Scholar
• Kaira K, Oriuchi N, Imai H, et al. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol 2009;16(12):3473-81
   PubMed Web of Science ®Google Scholar
• Huang PY, Best OG, Almazi JG, et al. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk Lymphoma 2014;55(9):2085-92
   PubMed Web of Science ®Google Scholar
• Henderson NC, Collis EA, Mackinnon AC, et al. CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation. J Biol Chem 2004;279(52):54731-41
   PubMedGoogle Scholar
• Hara K, Kudoh H, Enomoto T, et al. Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98. Biochem Biophys Res Commun 1999;262(3):720-5
   PubMedGoogle Scholar
• Feral CC, Nishiya N, Fenczik CA, et al. CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci USA 2005;102(2):355-60
   PubMed Web of Science ®Google Scholar
• Shennan DB, Thomson J. Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol Rep 2008;20(4):885-9
   PubMed Web of Science ®Google Scholar
• Imai H, Kaira K, Oriuchi N, et al. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res 2010;30(12):4819-28
   PubMed Web of Science ®Google Scholar
• Cai S, Bulus N, Fonseca-Siesser PM, et al. CD98 modulates integrin beta1 function in polarized epithelial cells. J Cell Sci 2005;118(Pt 5):889-99
   PubMedGoogle Scholar
• Rintoul RC, Buttery RC, Mackinnon AC, et al. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell 2002;13(8):2841-52
   PubMed Web of Science ®Google Scholar
• Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009;136(3):521-34
   PubMed Web of Science ®Google Scholar
• Fukumoto S, Hanazono K, Fu DR, et al. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model. Biochem Biophys Res Commun 2013;439(1):103-8
   PubMedGoogle Scholar
• A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML. Available from: https://clinicaltrials.gov/ct2/show/NCT02040506
   Google Scholar
• Brodie KM, Henderson BR. Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem 2012;287(10):7701-16
   PubMedGoogle Scholar
• Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005;7(8):823-30
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 2012;3(2):137-51
   PubMedGoogle Scholar
• Stommel JM, Marchenko ND, Jimenez GS, et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999;18(6):1660-72
   PubMed Web of Science ®Google Scholar
• Kojima K, Kornblau SM, Ruvolo V, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 2013;121(20):4166-74
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012;120(9):1765-73
   PubMed Web of Science ®Google Scholar
• Etchin J, Sanda T, Mansour MR, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013;161(1):117-27
   PubMed Web of Science ®Google Scholar
• Safety study of the selective inhibitor of nuclear export (SINE) KPT-330 in Patients With Advanced Hematological Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01607892
   Google Scholar
• Savona M, Garzon R. Brown PdN, Yee K, Lancet JE, Gutierrez M, et al. Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML) [abstract]. Blood 2013;122(21):1440
   Google Scholar
• Ranganathan P, Yu X, Hofstetter J, et al. Decitabine priming enhances the antileukemic effects of the selective inhibitor of nuclear export (SINE) CRM1/XPO1 Antagonist (Selinexor) In Acute Myeloid Leukemia (AML) [abstract]. Blood 2013;122(21);1453
   Google Scholar
• Decitabine and selinexor in treating patients with relapsed or refractory acute myeloid leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02093403
   Google Scholar
• Selinexor (KPT-330) in Older Patients With Relapsed AML (SOPRA). Available from: https://clinicaltrials.gov/ct2/show/NCT02088541
   Google Scholar
• Phase I trial of the selective inhibitor of nuclear export, kpt-330, in relapsed childhood ALL and AML. Available from: https://clinicaltrials.gov/ct2/show/NCT02091245
   Google Scholar
• Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001;8(4):189-91
   PubMed Web of Science ®Google Scholar
• Ruben JM, Visser LL, Bontkes HJ, et al. Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. Immunotherapy 2013;5(8):859-68
   PubMedGoogle Scholar